Include green vegetables in your diet to prevent memory loss

Agencies
December 21, 2017

Dec 21: Eating one serving of leafy greens per day may stave off memory loss in old age and keep the brain more youthful, according to new research.

The difference found between elderly people who ate greens and those who did not was stunning: the equivalent of being 11 years younger in age, said the study, published in the journal Neurology. While the research was based on survey responses and therefore fell short of proving cause and effect, researchers said it offers further evidence of the association between healthy eating and healthy ageing.

“Adding a daily serving of green, leafy vegetables to your diet may be a simple way to foster your brain health,” said study author Martha Clare Morris of Rush University Medical Center in Chicago.

The study tracked 960 people with an average age of 81, and followed them for an average of nearly five years. None had dementia upon entering the study. Participants completed questionnaires that asked how often they ate certain foods, including spinach, kale, collard greens and lettuce. They also had their thinking and memory skills tested once a year.

People who ate the most greens averaged about 1.3 servings per day. Those on the opposite end of the spectrum ate 0.1 servings per day. A serving is about a half cup, cooked. People who ate at least one serving daily “had a slower rate of decline on tests of memory and thinking skills than people who never or rarely ate these vegetables,” said the study.

These results persisted even after researchers accounted for factors like smoking, high blood pressure, obesity, education level and mental and physical exercise. “These observations are consistent with a broader body of evidence suggesting that people adhering to a Mediterranean diet may reduce their risk of dementia,” said David Llewellyn, senior research fellow in clinical epidemiology at the University of Exeter, in England, who was not involved in the study.

One key aspect of the so-called Mediterranean diet is consuming plant-based foods, while limiting the intake of red meat. James Pickett, head of research at the Alzheimer’s Society in London, pointed out that “the researchers did not directly look at dementia, so we cannot say that it would delay or prevent the onset of the condition.

“However, older people who ate one or two servings of Vitamin K-rich food per day performed better on memory tests than those who didn’t,” he added.

“A healthy diet rich in essential nutrients, combined with regular exercise and avoiding smoking, can help to reduce your risk of developing dementia.”

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 4,2020

The Union health ministry on Friday revised the dosage of anti-viral drug remdesivir to be administered to coronavirus patients in the moderate stage of illness from the earlier six days to five days as it issued an updated 'Clinical Management Protocols for COVID-19'.

The drug, administered in the form of injection, should be given at a dose of 200 mg on day one followed by 100 mg daily for four days (total five days), the new treatment protocols stated.

The Health Ministry on June 13 had allowed the use of remdesivir for restricted emergency use in moderate cases under "investigational therapies".

"Under emergency use authorisation, remdesivir may be considered for patients in moderate stage requiring oxygen support," the document stated.

It is not recommended for those with severe renal impairment and high level of liver enzymes, pregnant and lactating women, and those below 12 years, it said.

The ministry also okayed off-label application of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma for treating COVID-19 patients in the moderate stage of illness as "investigational therapies".

It also recommended hydroxychloroquine for patients during the early course of the disease and not for critically-ill patients.

On June 27, the ministry had included an inexpensive, widely used steroid dexamethasone in treatment protocols for COVID-19 patients in the moderate to severe stages of their illness among other therapeutic measures.

The ministry advised use of dexamethasone, which is already used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects, as an alternative choice to methylprednisolone for managing moderate to severe cases of coronavirus infection.

India's COVID-19 cases soared by over 20,000 in a day for the first time taking the country's total tally to 6,25,544 on Friday while the death toll climbed to 18,213 with 379 new fatalities, according to the Union Health Ministry data updated at 8 am.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 26,2020

Tedros Adhanom Ghebreyesus, the World Health Organisation's (WHO) Director-General, said that a clinical trial of hydroxychloroquine (HCQ) on COVID-19 patients has come to "a temporary pause", while the safety data of the the anti-malaria drug was being reviewed.

According to the WHO chief, The Lancet medical journal on May 22 had published an observational study on HCQ and chloroquine and its effects on COVID-19 patients that have been hospitalized, reports Xinhua news agency.

The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

"The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday (May 23) and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally," Tedros said in a virtual press conference on Monday.

The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug, he said.

"The Executive Group has implemented a temporary pause of the HCQ arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board. The other arms of the trial are continuing," Tedros added.

WHO initiated the Solidarity Trial, a plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19 more than two months ago, which include HCQ.

According to the WHO, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries under the Solidarity Trial.

Tedros added that the safety concern over the drug related only to the use of HCQ and chloroquine in COVID-19, and "these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria".

"WHO will provide further updates as we know more," he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.